Arya Pharma (Pty) Ltd controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2026
Sahpra orders recall of four batches of Enalapril 10mg Arya
Recall announced
The South African Health Products Regulatory Authority (Sahpra) ordered the recall of four batches of Enalapril 10mg Arya, a hypertension medicine, after post-marketing inspections flagged out-of-specification results. The recall is classified as Class II-Type A and is being implemented by Arya Pharma (Pty) Ltd in consultation with Sahpra. Patients, healthcare professionals, pharmacies, wholesalers and other suppliers are urged to check stock and stop dispensing the affected batches.
Stated objective. to protect patients and safeguard public health
Company response
Recall — Arya Pharma (Pty) Ltd
Sahpra said the recall is classified as a Class II-Type A recall and is being implemented by Arya Pharma (Pty) Ltd in consultation with Sahpra in accordance with the Medicines and Related Substances Act 101 of 1965 as amended.
Source excerpt
The recall follows post‑marketing inspections that flagged out‑of‑specification results, prompting urgent action to protect patients and safeguard public health.
Sahpra said the recall is classified as a Class II-Type A recall and is being implemented by Arya Pharma (Pty) Ltd in consultation with Sahpra in accordance with the Medicines and Related Substances Act 101 of 1965 as amended.